232 related articles for article (PubMed ID: 21083700)
1. Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes.
Bao YQ; Zhou M; Zhou J; Lu W; Gao YC; Pan XP; Tang JL; Lu HJ; Jia WP
Clin Exp Pharmacol Physiol; 2011 Jan; 38(1):50-4. PubMed ID: 21083700
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
[TBL] [Abstract][Full Text] [Related]
3. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G
Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
[TBL] [Abstract][Full Text] [Related]
6. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
8. The effect of an alpha-glucosidase inhibitor and insulin on glucose metabolism and lipid profiles in non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Hamada H; Tanokuchi S; Ichiki K; Ota Z
J Int Med Res; 1996; 24(5):438-47. PubMed ID: 8895048
[TBL] [Abstract][Full Text] [Related]
9. Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial.
Reed J; Dong T; Eaton E; Friswold J; Porges J; Al-Kindi SG; Rajagopalan S; Neeland IJ
Diabetes Obes Metab; 2024 Jul; 26(7):2881-2889. PubMed ID: 38680050
[TBL] [Abstract][Full Text] [Related]
10. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
Bao YQ; Zhou J; Zhou M; Cheng YJ; Lu W; Pan XP; Tang JL; Lu HJ; Jia WP
Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
He YL; Foteinos G; Neelakantham S; Mattapalli D; Kulmatycki K; Forst T; Taylor A
Diabetes Obes Metab; 2013 Dec; 15(12):1111-9. PubMed ID: 23782529
[TBL] [Abstract][Full Text] [Related]
12. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.
Torekov SS; Holst JJ; Ehlers MR
Diabetes Obes Metab; 2014 May; 16(5):451-6. PubMed ID: 24251641
[TBL] [Abstract][Full Text] [Related]
13. Strong correlation between glycaemic variability and total glucose exposure in type 2 diabetes is limited to subjects with satisfactory glycaemic control.
Suh S; Joung JY; Jin SM; Kim MY; Bae JC; Park HD; Lee MS; Lee MK; Kim JH
Diabetes Metab; 2014 Sep; 40(4):272-7. PubMed ID: 24630733
[TBL] [Abstract][Full Text] [Related]
14. Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus.
Pratley RE; Rosenstock J; Heller SR; Sinclair A; Heine RJ; Kiljański J; Brusko CS; Duan R; Festa A
J Diabetes Sci Technol; 2018 Nov; 12(6):1184-1191. PubMed ID: 29893144
[TBL] [Abstract][Full Text] [Related]
15. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study.
Manski-Nankervis J; Yates CJ; Blackberry I; Furler J; Ginnivan L; Cohen N; Jenkins A; Vasanthakumar S; Gorelik A; Young D; Best J; O'Neal D
Diabet Med; 2016 Jun; 33(6):803-11. PubMed ID: 26435033
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
[TBL] [Abstract][Full Text] [Related]
18. Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
Park SE; Lee BW; Kim JH; Lee WJ; Cho JH; Jung CH; Lee SH; Suh S; Hur GC; Kim SH; Jang YH; Park CY;
Diabetes Obes Metab; 2017 Jun; 19(6):892-896. PubMed ID: 28058753
[TBL] [Abstract][Full Text] [Related]
19. Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients.
Saito N; Sakai H; Suzuki S; Sekihara H; Yajima Y
J Int Med Res; 1998; 26(5):219-32. PubMed ID: 9924706
[TBL] [Abstract][Full Text] [Related]
20. How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?
Inzucchi SE; Umpierrez G; DiGenio A; Zhou R; Kovatchev B
Diabetes Res Clin Pract; 2015 Apr; 108(1):179-86. PubMed ID: 25661664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
